The mechanisms of immune evasion during haematological malignancies are poorly understood. As lymphomas grow in lymphoid organs, it would be expected that if these lymphomas express neo-antigens they should be readily detected by the immune system. To test this assumption, we generated a new non-Hodgkin B-cell lymphoma model expressing the model tumour neo-antigen Ovalbumin (OVA), and analysed the endogenous antigen-specific CD8(+) T-cell response that it elicited in recipient mice. The OVA+ lymphoma cells were eliminated by cytotoxic T lymphocytes (CTL) in mice that had been previously vaccinated against OVA. In contrast, the immune system of naïve mice ignored the malignant cells even though these continuously expressed and presented OVA ...
There is evidence showing that high avidity CTLs can be more effective than low avidity CTLs for ado...
International audienceHuman B-cell lymphomas, the fourth most common hematologic malignancy, are cur...
Cancer vaccines are a novel method of treating cancer by harnessing the patient’s own immune system ...
Abstract: Growth of cancer in rodent models and in patients elicits immune responses directed toward...
CD8+ T cells have the potential to influence the outcome of cancer pathogenesis, including complete ...
International audienceThese last 20 years, research on immune tumor microenvironment led to identify...
Trioma cell vaccination is a potent new immunologic approach for the therapy of malignant B-cell lym...
The development of effective therapeutic vaccines to generate tumor-reactive cyto-toxic T lymphocyte...
While the cellular origin of lymphoma is often characterized by chromosomal translocations and other...
Immunoglobulin (Ig) variable (V) region idiotypes (Id’s) are highly tumor-specific antigens produced...
Relapses occurring in most patients with lymphoma after antibody or chemo-therapy highlight a need f...
The development of malignant disease might be seen as a failure of immune surveillance. However, not...
Background Immunotherapy of cancer is successful but tumor regression often is incomplete and follow...
© 2014 Dr. Gabriela Segal WassermanThe immune system protects the body from potential dangers and me...
Cancer immunoediting is a process by which immune cells, particularly lymphocytes of the adaptive im...
There is evidence showing that high avidity CTLs can be more effective than low avidity CTLs for ado...
International audienceHuman B-cell lymphomas, the fourth most common hematologic malignancy, are cur...
Cancer vaccines are a novel method of treating cancer by harnessing the patient’s own immune system ...
Abstract: Growth of cancer in rodent models and in patients elicits immune responses directed toward...
CD8+ T cells have the potential to influence the outcome of cancer pathogenesis, including complete ...
International audienceThese last 20 years, research on immune tumor microenvironment led to identify...
Trioma cell vaccination is a potent new immunologic approach for the therapy of malignant B-cell lym...
The development of effective therapeutic vaccines to generate tumor-reactive cyto-toxic T lymphocyte...
While the cellular origin of lymphoma is often characterized by chromosomal translocations and other...
Immunoglobulin (Ig) variable (V) region idiotypes (Id’s) are highly tumor-specific antigens produced...
Relapses occurring in most patients with lymphoma after antibody or chemo-therapy highlight a need f...
The development of malignant disease might be seen as a failure of immune surveillance. However, not...
Background Immunotherapy of cancer is successful but tumor regression often is incomplete and follow...
© 2014 Dr. Gabriela Segal WassermanThe immune system protects the body from potential dangers and me...
Cancer immunoediting is a process by which immune cells, particularly lymphocytes of the adaptive im...
There is evidence showing that high avidity CTLs can be more effective than low avidity CTLs for ado...
International audienceHuman B-cell lymphomas, the fourth most common hematologic malignancy, are cur...
Cancer vaccines are a novel method of treating cancer by harnessing the patient’s own immune system ...